We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer's (PFE) Trumenba Accepted for Review in the EU
Read MoreHide Full Article
Pfizer Inc. (PFE - Free Report) announced that the European Medicines Agency has accepted for review the marketing authorization application for Trumenba (meningococcal group B vaccine). The acceptance marks the initiation of the EMA’s review process for the vaccine.
Pfizer is looking to get Trumenba approved for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals aged 10 years and older.
We note that Trumenba gained accelerated approval in the U.S. for active immunization for the prevention of invasive disease caused by Neisseria meningitidis serogroup B in individuals aged 10 through 25 years of age. The company is currently looking to convert accelerated approval to traditional approval.
Pfizer, Spark Therapeutics Report New Hemophilia B Data
Also, Pfizer and Spark Therapeutics announced encouraging new data from initial patients dosed in the phase I/II study on SPK-9001, which is being evaluated for the treatment of hemophilia B. Spark Therapeutics' shares jumped 14.4% on the news. Overall, the shares gained 23.3% on the news.
Data showed that the first three patients enrolled in the study witnessed adeno-associated virus -mediated factor IX activity levels following one administration of SPK-9001 at the initial low dose level. Additionally, none of the three patients received regular infusions of factor IX concentrates to prevent bleeding events found over the combined 28 weeks of observation. On the safety front, SPK-9001 was found to be well-tolerated and none of the patients required or received immunosuppression.
Both companies intend to present an expanded dataset on the first cohort at the meeting of the European Hematology Association next month.
We note that Pfizer and Spark Therapeutics entered into a collaboration in 2014 under which Spark Therapeutics will be responsible for conducting all phase I/II studies for any candidate that may be developed under its SPK-FIX program. On the other hand, Pfizer will be accountable for pivotal studies, any regulatory activity and global commercialization of any product that may result from the collaboration.
Pfizer is a Zacks Rank #1 (Strong Buy) stock. A couple of other top-ranked stocks in the health care sector are Bristol-Myers Squibb Company (BMY - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) , each sporting the same Zacks Rank as Pfizer.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer's (PFE) Trumenba Accepted for Review in the EU
Pfizer Inc. (PFE - Free Report) announced that the European Medicines Agency has accepted for review the marketing authorization application for Trumenba (meningococcal group B vaccine). The acceptance marks the initiation of the EMA’s review process for the vaccine.
Pfizer is looking to get Trumenba approved for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals aged 10 years and older.
We note that Trumenba gained accelerated approval in the U.S. for active immunization for the prevention of invasive disease caused by Neisseria meningitidis serogroup B in individuals aged 10 through 25 years of age. The company is currently looking to convert accelerated approval to traditional approval.
Pfizer, Spark Therapeutics Report New Hemophilia B Data
Also, Pfizer and Spark Therapeutics announced encouraging new data from initial patients dosed in the phase I/II study on SPK-9001, which is being evaluated for the treatment of hemophilia B. Spark Therapeutics' shares jumped 14.4% on the news. Overall, the shares gained 23.3% on the news.
Data showed that the first three patients enrolled in the study witnessed adeno-associated virus -mediated factor IX activity levels following one administration of SPK-9001 at the initial low dose level. Additionally, none of the three patients received regular infusions of factor IX concentrates to prevent bleeding events found over the combined 28 weeks of observation. On the safety front, SPK-9001 was found to be well-tolerated and none of the patients required or received immunosuppression.
Both companies intend to present an expanded dataset on the first cohort at the meeting of the European Hematology Association next month.
We note that Pfizer and Spark Therapeutics entered into a collaboration in 2014 under which Spark Therapeutics will be responsible for conducting all phase I/II studies for any candidate that may be developed under its SPK-FIX program. On the other hand, Pfizer will be accountable for pivotal studies, any regulatory activity and global commercialization of any product that may result from the collaboration.
Pfizer is a Zacks Rank #1 (Strong Buy) stock. A couple of other top-ranked stocks in the health care sector are Bristol-Myers Squibb Company (BMY - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) , each sporting the same Zacks Rank as Pfizer.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>